Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Pritchard, Adam J ^a   Mir, Anis K ^b   Dev, Kumlesh K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 6; LYSOPHOSPHATIDYLCHOLINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AUTACOID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL ISOLATION; CELL MIGRATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; FEMALE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; SLICE CULTURE; SPLEEN CELL; ANALOGS AND DERIVATIVES; ANIMAL; CEREBELLUM; CYTOLOGY; DEMYELINATING DISEASE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PATHOLOGY; SPLEEN; T LYMPHOCYTE; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

ANIMALS; CEREBELLUM; COCULTURE TECHNIQUES; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; MICE; MICE, TRANSGENIC; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PHENOTYPE; PROPYLENE GLYCOLS; SPHINGOSINE; SPLEEN; T-LYMPHOCYTES; TISSUE CULTURE TECHNIQUES;

EID: 84902603087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099444     Document Type: Article

References (59)

1. Lee M, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, et al. (1998) Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1. Science (80-) 279: 1552-1555.
2. Yamazaki Y, Kon J, Sato K, Tomura H, Sato M, et al. (2000) Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway. Biochem Biophys Res Commun 268: 583-589. (Pubitemid 30119665)
3. Im D-S, Heise CE, Ancellin N, O'Dowd BF, Shei G-J, et al. (2000) Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 275: 14281-14286. (Pubitemid 30339709)
4. Okamoto H, Takuwa N, Yatomi Y, Gonda K, Shigematsu H, et al. (1999) EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16. Biochem Biophys Res Commun 260: 203-208. (Pubitemid 29351808)
5. An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, et al. (1997) Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett 417: 279-282. (Pubitemid 27511604)
6. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 :355-60. (Pubitemid 38133663)
7. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, et al. (2010) A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med 362: 387-401.
8. Taha T, Hannun Y, Obeid L (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131.
9. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616. (Pubitemid 39025055)
10. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, et al. (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107: 1454-1458. (Pubitemid 43242381)
11. Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, et al. (2005) Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 280: 36865-36872. (Pubitemid 41587768)
12. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457. (Pubitemid 34952287)
13. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349. (Pubitemid 34303689)
14. Sun Y, Wang W, Shan B, Di J, Chen L, et al. (2011) FTY720-induced conversion of conventional Foxp3- CD4 + T cells to Foxp3+ regulatory T cells in NOD mice. Am J Reprod Immunol 66: 349-362.
15. Sehrawat S, Rouse BT (2008) Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. J Immunol 180: 7636-7647.
16. Fontenot J, Gavin M, Rudensky A (2003) Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 4: 330-336. (Pubitemid 36432314)
17. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C (2007) In vitro generation of CD4+ CD25 + regulatory cells from murine naive T cells. Nat Protoc 2: 1789-1794.
18. Wolf AM, Eller K, Zeiser R, Gerlach U V, Sixt M, et al. (2009) The Sphingosine 1-phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo. J Immunol 183: 3751-3760.
19. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, et al. (2008) Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77-93. (Pubitemid 350192672)
20. Pritchard AJ, Dev KK (2013) The role of S1P receptors in the treatment of demyelinating diseases. Future Neurology 8: 487-489.
21. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, et al. (2010) Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 176: 2682-2694.
22. Sheridan GK, Dev KK (2012) S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia 60: 382-392.
23. Ling C, Verbny Y, Banks M (2008) In situ activation of antigen-specific CD8+ T cells in the presence of antigen in organotypic brain slices. J Immunol 180: 8393-8399.
24. Prodinger C, Bunse J, Krüger M, Schiefenhövel F, Brandt C, et al. (2011) CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol 121: 445-458.
25. Kim HJ, Miron VE, Dukala D, Proia RL, Ludwin SK, et al. (2011) Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J 25: 1509-1518.
26. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, et al. (2005) Edg8/ S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25: 1459-1469. (Pubitemid 40250722)
27. Hu Y, Lee X, Ji B, Guckian K, Apicco D, et al. (2011) Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol Cell Neurosci 48: 72-81.
28. Jackson SJ, Giovannoni G, Baker D (2011) Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation 8: 76.
29. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, et al. (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197: 1073-1081. (Pubitemid 36570063)
30. Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, et al. (2013) Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br J Pharmacol 169: 1114-1129.
31. Yang Y, Lewis R, Miller RH (2011) Interactions between oligodendrocyte precursors control the onset of CNS myelination. Dev Biol. 350:127-38.
32. Bin JM, Leong SY, Bull SJ, Antel JP, Kennedy TE (2012) Oligodendrocyte precursor cell transplantation into organotypic cerebellar shiverer slices: a model to study myelination and myelin maintenance. PLoS One. 7:e41237.
33. Shrestha R, Millington O, Brewer J, Dev KK, Bushell TJ (2014) Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways. Neuropharmacology 76:184-93.
34. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, et al. (2007) FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 178: 2458-2468. (Pubitemid 46233446)
35. Liao J-J, Huang M-C, Goetzl EJ (2007) Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 178: 5425-5428. (Pubitemid 46674335)
36. Murphy AC, Lalor SJ, Lynch MA, Mills KHG (2010) Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 24: 641-651.
37. Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, et al. (2013) In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med 5: 170ra15.
38. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, et al. (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/ p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153: 801-813. (Pubitemid 28419033)
39. Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, et al. (1999) Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand J Immunol 49: 554-561. (Pubitemid 29243129)
40. Dorsam G, Graeler MH, Seroogy C, Kong Y, Voice JK, et al. (2003) ransduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J Immunol 171: 3500-3507. (Pubitemid 37254552)
41. Oz-Arslan D, Ruscher W, Myrtek D, Ziemer M, Jin Y, et al. (2006) IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids and immunoblot analyses indicate that immature as. J Leukoc Biol 80: 287-297. (Pubitemid 44835502)
42. PotìF, Gualtieri F, Sacchi S, Weiben-Plenz G, Varga G, et al. (2013) KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol 33: 1505-1512.
43. Noda H, Takeuchi H, Mizuno T, Suzumura A (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 256: 13-18.
44. Sensken S, Bode C, Gräler M (2009) Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J. Pharmacol. Exp. Ther. 328: 963-969.
45. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, et al. (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5: 428-435.
46. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, et al. (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121: 2290-2300.
47. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, et al. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089. (Pubitemid 47093504)
48. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 108:751-756.
49. Müller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35: 533-545. (Pubitemid 40331330)
50. Idzko M, Panther E, Corinti S, Morelli A, Ferrari D, et al. (2002) Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 16: 625-627.
51. Hwang SJ, Kim JH, Kim HY, Kim S, Chung DH (2010) FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration. Lab Investig 90: 9-19.
52. Sepulcre J, Sanchez-Ibarrola A, Moreno C, de Castro P (2005) Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis. Cytokine 32: 111-116. (Pubitemid 41563041)
53. Buntinx M, Ameloot M, Steels P, Janssen P, Medaer R, et al. (2002) Interferon-gamma-induced calcium influx in T lymphocytes of multiple sclerosis and rheumatoid arthritis patients: a complementary mechanism for T cell activation? J Neuroimmunol 124: 70-82. (Pubitemid 34212012)
54. Panitch H, Haley A, Hirsch R, Johnson K (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 329: 893-895.
55. Aloisi F, Ria F, Adorini L (2000) Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21: 141-147.
56. Stelmasiak Z, Koziol-Montewka M, Dobosz B, Rejdak K, Bartosik-Psujek H, et al. (2000) Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 6: 1108-1108.
57. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45.
58. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurol 47 : 1531-1534. (Pubitemid 26422549)
59. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888. (Pubitemid 33096700)